0 likes | 10 Views
The global migraine drugs market size was valued at USD 4.8 billion in 2022 and is poised to grow at a significant CAGR of 8.4% during the forecast period 2023-29. It also includes market size and projection estimations for each of the five major regions from 2023 to 2029. The research report includes historical data, trending features, and market growth estimates for the future. Furthermore, the study includes a global and regional estimation and further split by nations and categories within each region. The research also includes factors and barriers to the migraine drugs market growth, as
E N D
Market Overview: The Global Migraine Drugs Market size was valued at USD 4.8 billion in 2022 and is poised to grow at a significant CAGR of 8.4% during the forecast period 2023-29. The Migraine Drugs Market research report also provides opportunities for business owners to exploit through use of relevant approaches. The study’s prospects assist stakeholders and report purchasers in properly planning their investments and augmenting their profits. The report provides a quantitative analysis of the market segments, trends, estimations, and dynamics of the Migraine Drugs Market analysis from 2023 to 2029 to identify the prevailing market opportunities. In addition, the report discusses the implications of COVID-19, including the industry's initial response and strategies for ensuring business continuity in the coming years. View Detailed Report Description 2
Market Segments: The Migraine Drugs Market has been fragmented based on: 1) By Drug Type: Prophylactic, (Topiramate, Botulinum toxin) 2) By Abortive: Ergot Alkaloids, Triptans 3) By Route of Administration: Injectables, Oral 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others 5) By Geography: Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe Request Sample Report 3
Key Players: Some of the major key players in the Migraine Drugs Market are: • • • • • • • • • • • AstraZeneca Plc. (U.K.) Allergan Plc. (U.S.) Pfizer, Inc. (U.S.) Teva Pharmaceutical Industries Ltd. (Israel) GlaxoSmithKline plc (U.K) Eli Lilly & Co. (U.S.) Novartis AG (Switzerland) Merck & Co., Inc. (U.S.) Valeant Pharmaceutical International, Inc. (Canada) Janssen Pharmaceutical Company (Johnson & Johnson) (U.S.) Endo International plc. (U.S.) Request Sample Report 4
Europe Office: Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX Asia-Pacific Office: Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad – 500072 Email: sales@precisionbusinessinsights.com Toll-Free: +1-866-598-1553 5